Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel vs Docetaxel in mCRPC post-Abiraterone/Enzalutamide
NCT03764540Phase 2Terminated
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Apr 2019
- Primary completion
- Dec 2024
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Centre hospitalier de l’Université de Montréal. Started Apr 2019; status: terminated.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03764540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03764540.